Drug Trial Radar · NCT04463771
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
Last checked: Nov 19, 2026Latest source record: Jun 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
206
Actual
Start
Jan 26, 2021
Primary completion
May 29, 2026
Study completion May 29, 2026
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- Collaborators
- GOG Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT)
- First posted
- Jul 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, nonrandomized, Phase 2 umbrella study of retifanlimab in participants who have advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy. retifanlimab will be administered as monotherapy or in combination with other immunotherapy or targeted agents.
Conditions
- Endometrial Cancer
Interventions
retifanlimabDrug
INCMGA00012 administered intravenously on Day 1 of each 28-day cycle for up to 26 cycles.
epacadostatDrug
epacadostat will be administered orally BID.
pemigatinibDrug
pemigatinib will be administered orally QD.
INCAGN02385Drug
INCAGN2385 will be administered every 2 weeks
INCAGN02390Drug
INCAGN2390 will be administered every 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Group A - Objective Response RateTime frame: up to 2.5 years
Locations
65 sites in 7 countries. Site status is shown where the registry gives one.
Alaska Womens Cancer Care Akwcc
Anchorage, Alaska
Honorhealth
Phoenix, Arizona
Arizona Oncology Associates
Tucson, Arizona
UCLA Medical Hematology & Oncology
Los Angeles, California
Olive View Med Ctr
Sylmar, California
Broward Health Medical Center
Fort Lauderdale, Florida
Miami Cancer Institute
Miami, Florida
Mount Sinai Medical Center Comprehensive Cancer Center
Miami Beach, Florida
Advent Health Medical Group-Orlando 2501
Orlando, Florida
H. Lee Moffitt Cancer Center and Research Institute Hospital
Tampa, Florida
Georgia Cancer Center
Augusta, Georgia
Barbara Ann Karmanos Cancer Hospital
Detroit, Michigan
Minnesota Oncology-Maplewood
Coon Rapids, Minnesota
Midwest Cancer Care
Kansas City, Missouri
Washington University
St Louis, Missouri
Billings Clinic Cancer Center
Billings, Montana
Comprehensive Cancer Centers of Nevada
Henderson, Nevada
New Mexico Cancer Care Alliance
Albuquerque, New Mexico
Laura & Isaac Perlmutter Cancer Ctr
New York, New York
University of North Carolina At Chapel Hill
Chapel Hill, North Carolina
The Ohio State University Wexner Medical Center Division of Gynecologic Oncology
Hilliard, Ohio
Willamette Valley Cancer Institute
Eugene, Oregon
Texas Oncology-Tyler
Sioux Falls, South Dakota
Tennessee Oncology
Nashville, Tennessee
Texas Oncology-Austin Center
Austin, Texas
Texas Oncology-Fort Worth South Henderson
Fort Worth, Texas
Texas Oncology San Antonio
San Antonio, Texas
Texas Oncology the Woodlands
Shenandoah, Texas
Virginia Commonwealth University
Richmond, Virginia
O.L.V Ziekenhuis
Aalst, Belgium
Institut Jules Bordet
Brussels, Belgium
Ghent University Hospital
Ghent, Belgium
Universitaire Ziekenhuis Leuven - Gasthuisberg
Leuven, Belgium
Centre Hospitalier Universitaire de Liege - Sart Tilman
Liège, Belgium
Chu Ucl Namur de Saint Elisabeth
Namur, Belgium
Chu Besancon Hospital Jean Minjoz
Besançon, France
Institut Bergonie
Bordeaux, France
Hospital Cochin Cancerologie
Paris, France
Cario - Centre Armoricain de Radiotherapie Imagerie Medicale Et Oncologie
Plérin, France
Centre de Lutte Contre Le Cancer - Institut de Cancerologie de L'Ouest - Rene Gauducheau
Saint-Herblain, France
Showing 40 of 65 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.